“Efficacy and Safety of Biosimilar Cetuximab (CETUXA) in Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck: A Retrospective Multicenter Analysis.”. (2025) Journal of Carcinogenesis, 24(10s), pp. 382–389. doi:10.64149/J.Carcinog.24.10s.382-389.